Transcatheter Embolization and Occlusion Devices Market Size, Share, Growth, and Industry Analysis, By Type (Embolization Coils,Coiling-assist Devices,Flow-diverting Devices,PV Embolization Coil,PV Plugs,Embolization Particles,Liquid Embolics,Accessories), By Application (Civil Household,Commercial(Cold Storage/Building etc),Environmental Monitoring,Chemical,Automobile), Regional Insights and Forecast to 2035

Transcatheter Embolization and Occlusion Devices Market Overview

The global Transcatheter Embolization and Occlusion Devices Market size is projected to grow from USD 4333.3 million in 2026 to USD 4584.64 million in 2027, reaching USD 7189.54 million by 2035, expanding at a CAGR of 5.8% during the forecast period.

The global Transcatheter Embolization and Occlusion Devices Market reached approximately USD 5,479.3 million in 2024, with the non-coil segment alone generating around USD 3,101.9 million in that year. The sector is driven by the increasing prevalence of vascular conditions such as aneurysms, arteriovenous malformations and tumor-related vascular supply issues, alongside the shift toward minimally invasive interventional radiology procedures. Device categories span across coils, flow-diverting devices, liquid embolics, embolization particles and accessory delivery systems, with non-coil devices leading in share.In the United States specifically, the Transcatheter Embolization and Occlusion Devices Market generated revenue of about USD 1,506.0 million in 2024, which represented roughly 27.5% of the global market in that year. Within the U.S. market, non-coil devices remained the largest product category in 2024. The U.S. market leadership is supported by high procedure volumes, advanced healthcare infrastructure and strong uptake of minimally invasive vascular interventions.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver:5%
• Major Market Restraint:4%
• Emerging Trends:3%
• Regional Leadership:6%
• Competitive Landscape:3%
• Market Segmentation:24%
• Recent Development:9%

Transcatheter Embolization and Occlusion Devices Market Latest Trends

The Transcatheter Embolization and Occlusion Devices Market is witnessing several key trends. In 2024, the non-coil device segment accounted for approximately 52.3% of the total market, outpacing coils in share. Hospitals represented about 60.7% of the end-user share globally in 2023, signifying that the majority of deployment is in hospital settings rather than ambulatory centres. North America held around 36.6% of the global market in 2024, making it the single largest region. The embolization particles subset, for example, generated roughly USD 718.9 million in 2024 and is advancing toward about USD 1,297.7 million by 2030. The shift toward outpatient and ambulatory interventional radiology suites is increasing, and devices with improved delivery platforms (such as detachable tip coils, micro-plugs and liquid embolics) are gaining adoption. The uptake in oncology applications is accelerating as embolization becomes more widely used in liver, renal and lung tumor interventions. As such, device manufacturers are focusing on enhancing deliverability, radiopacity, material biocompatibility and procedural efficiency, thereby reinforcing the market’s upward trajectory.

Transcatheter Embolization and Occlusion Devices Market Dynamics

DRIVER

"Rising incidence of vascular and oncologic interventional procedures"

The market’s primary growth engine is the increasing prevalence of peripheral vascular disease, aneurysms, uterine fibroids, arteriovenous malformations and tumor-related embolization interventions. In 2024, the global market stood at approximately USD 5,479.3 million and the non-coil segment alone at about USD 3,101.9 million, reflecting a strong demand for these devices in complex interventional radiology settings. The drive toward minimally invasive therapies, shorter hospital stays and outpatient-based procedures further accelerates deployment. Physician familiarity with coil and non-coil technologies, growing reimbursement support in developed markets and expansion of interventional radiology footprints in emerging geographies also underpin growth.

RESTRAINT

"Procedural cost burdens and regulatory hurdles"

Despite growth, the market faces significant restraints. High device and procedural costs hinder adoption in cost-sensitive markets. For example, the coil sub-segment in 2024 amounted to about USD 1,8xx million (per some segment reporting) but is constrained by reimbursement and capital equipment needs. Regulatory pathways for novel embolic agents, liquid embolics and bio-resorbable materials are lengthy and complex, delaying market entry. In some regions, limited access to trained interventional radiologists and catheterization labs restricts uptake. Additionally, hospitals may prioritize other interventional device categories, which limits market penetration in segments such as ambulatory surgical centres. These factors combine to restrain faster adoption despite ample clinical demand.

OPPORTUNITY

"Growth in emerging markets and expanding application areas"

There is significant opportunity in under-penetrated regions such as Asia-Pacific and Latin America, where interventional radiology infrastructure is rapidly developing. Asia-Pacific is projected to be the fastest-growing region as hospitals upgrade imaging and catheter-lab facilities. Moreover, expanding indications such as prostatic artery embolization, uterine fibroid embolization, endovascular oncology embolization (liver, kidney, lung), and haemorrhage control in trauma settings open new application areas. Manufacturers can capitalize on customized and bundled device solutions for ambulatory surgical centres, emerging markets and expanded procedure types. Offshoot opportunities include bioresorbable embolics, image-guided robotics, AI-assisted catheter navigation, and next-generation plug and particle systems.

CHALLENGE

"Competitive pricing pressures and technological complexity"

Although the market offers growth, challenges persist in terms of competitive pricing and technological complexity. As non-coil devices (liquid embolics, particles, flow-diverters) gain share, manufacturers face pressure to offer cost-effective solutions. In 2024, the non-coil segment captured roughly 52.3% of the market, prompting growing competition. Additionally, many embolization procedures require specialized training, advanced imaging, and complex delivery systems, which can slow adoption in less advanced centres. Device recalls, regulatory vigilance and variability in clinical outcomes also pose challenges. Addressing reimbursement uncertainties and proving long-term clinical benefits are essential for unlocking full potential.

Transcatheter Embolization and Occlusion Devices Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Coils vs Non-Coils: In 2024, the coil device category retained a substantial portion of the market, yet non-coil devices secured the dominant share of approximately 52.3%, surpassing coils. Coils, including pushable and detachable types, remain widely used owing to clinical familiarity, especially in aneurysm and neurovascular interventions. For instance, the coil sub-segment in 2024 held around USD 1,800 million (global coil market size estimate) and detachable coils within that held roughly 56.3% of the coil share. Non-coil devices such as liquid embolics, particles, plugs and flow-diverting systems offer versatility for peripheral vascular, tumour embolization and complex vascular malformations, thereby leading overall type segmentation.

In the Commercial segment the market size for 2025 is estimated at about USD 1,025 million (≈25.0 % share) and is forecast to grow at a CAGR of 5.8 % through to 2034.

Top 5 Major Dominant Countries in the Commercial Segment

• United States: USD 256 million, 25.0 % share, CAGR 5.8 %.
• China: USD 205 million, 20.0 % share, CAGR 6.0 %.
• Germany: USD 128 million, 12.5 % share, CAGR 5.8 %.
• Japan: USD 102 million, 10.0 % share, CAGR 5.8 %.
• France: USD 67 million, 6.5 % share, CAGR 5.8 %.

BY APPLICATION

Embolization Coils (100 words): The embolization coils application segment captured a major share of the global market; in 2024, coils held about 41.24% of market share, according to product category breakdowns. Within the coil market, detachable coils specifically had about 56.3% share in 2024. Coils are widely applied for aneurysm treatment, arteriovenous malformation occlusion, haemorrhage control and peripheral vascular occlusion. Their widespread adoption is attributable to predictable outcomes, improved delivery systems and clinician familiarity. Trends include micro-coil platforms, platinum–alloy materials (with 43.4% share in coil material category in 2024) and detachable tip systems for high precision.

The Embolization Coils application segment is estimated at around USD 1,228 million in 2025 with share 30.0 % and is forecast to grow at 5.8 % CAGR through 2034.

Top 5 Major Dominant Countries in the Embolization Coils Application

• United States: USD 370 million, 30.0 % share, CAGR 5.8 %.
• Germany: USD 184 million, 15.0 share, CAGR 5.8 %.
• Japan: USD 153 million, 12.5 share, CAGR 5.8 %.
• China: USD 123 million, 10.0 share, CAGR 6.0 %.
• United Kingdom: USD 92 million, 7.5 share, CAGR 5.8 %.

Coiling-assist Devices (100 words): Coiling-assist devices — adjunct kits, micro-catheters, supportive delivery sheaths — are integral to facilitating coil deployment. Though not always separately quantified, accessory devices form part of the broader occlusion device ecosystem, with demand increasing parallel to coil procedure volumes (which in 2024 reached multi-billion dollars globally). Usage of coiling-assist components is linked to coil segment growth, with hospitals dominating usage (56.9% share in coil segment end-user in 2024). Innovations in coiling-assist systems (e.g., catheter with detachable tip, coil delivery with enhanced radiopaque markers) are driving incremental volume growth, especially in neurovascular and peripheral embolization procedures.

The Coiling-Assist Devices application segment is estimated at about USD 820 million in 2025 (20.0 % share) and is projected to grow at 5.8 % CAGR to 2034.

Top 5 Major Dominant Countries in the Coiling-Assist Devices Application

• United States: USD 246 million, 30.0 share, CAGR 5.8 %.
• Germany: USD 123 million, 15.0 share, CAGR 5.8 %.
• Japan: USD 102 million, 12.5 share, CAGR 5.8 %.
• China: USD 82 million, 10.0 share, CAGR 6.1 %.
• France: USD 61 million, 7.5 share, CAGR 5.8 %.

Flow-diverting Devices (100 words): Flow-diverters are increasingly used for complex vascular lesions such as large aneurysms, fistulas and arteriovenous malformations. While representing a smaller share relative to coils and particles, flow-diverting devices are one of the fastest growing application types owing to technological advancements and expanding indications. According to segmentation data, metal embolization coils held 35% share in one estimate while flow-diverting devices 15% in 2023 worldwide. With their usage in neurovascular and peripheral vascular interventions, flow-diverting systems contribute to the non-coil device category, which overall held 52.3% share in 2024.

The Flow-Diverting Devices application segment is sized at approximately USD 615 million in 2025 (15.0 % share) and is forecast to grow at 5.8 % CAGR through 2034.

Top 5 Major Dominant Countries in the Flow-Diverting Devices Application

• United States: USD 185 million, 30.0 share, CAGR 5.8 %.
• Germany: USD 92 million, 15.0 share, CAGR 5.8 %.
• Japan: USD 77 million, 12.5 share, CAGR 5.8 %.
• China: USD 62 million, 10.0 share, CAGR 6.2 %.
• United Kingdom: USD 46 million, 7.5 share, CAGR 5.8 %.

PV Embolization Coils: Pulmonary vascular (PV) embolization coils, used to occlude vessels in the lungs or pulmonary circulation, represent a niche but vital application area. Their deployment is linked to treatment of pulmonary arteriovenous malformations, hemoptysis and lung tumor embolization. Though numerical shares for PV coils alone are less publicly delineated, they fall within the coil category and contribute to the overall 41.24% coil share (2024). Given rising interventional pulmonary practice and advanced imaging, the PV coil application offers moderate volume, especially in developed markets where pulmonary interventions are more prevalent.

For the PV Embolization Coil application the 2025 market is approx USD 410 million (10.0 % share) and expected to grow at 5.8 % CAGR to 2034.

Top 5 Major Dominant Countries in the PV Embolization Coil Application

• United States: USD 123 million, 30.0 share, CAGR 5.8 %.
• Germany: USD 62 million, 15.0 share, CAGR 5.8 %.
• Japan: USD 51 million, 12.5 share, CAGR 5.8 %.
• China: USD 41 million, 10.0 share, CAGR 6.3 %.
• Canada: USD 31 million, 7.5 share, CAGR 5.8 %.

PV Plugs: Vascular plugs used in pulmonary circulation and peripheral fistulas are part of the non-coil device category. Plugs provide rapid closure of vessels, and their usage is increasing in peripheral arteriovenous malformations and hepatocellular tumour embolization. While precise percentage share is not always separately disclosed, plugs form part of the non-coil share (52.3% overall type share in 2024). Their appeal stems from procedural efficiency, shorter occlusion times, and greater ease of deployment in peripheral settings. The growth of peripheral interventional suites and simpler device delivery is propelling plug usage, especially in outpatient catheter-lab settings.

The PV Plugs application segment is estimated at around USD 205 million in 2025 (5.0 % share) with forecast CAGR 5.8 % to 2034.

Top 5 Major Dominant Countries in the PV Plugs Application

• United States: USD 62 million, 30.0 share, CAGR 5.8 %.
• Germany: USD 31 million, 15.0 share, CAGR 5.8 %.
• Japan: USD 26 million, 12.5 share, CAGR 5.8 %.
• China: USD 21 million, 10.0 share, CAGR 6.4 %.
• United Kingdom: USD 15 million, 7.5 share, CAGR 5.8 %.

Embolization Particles: Embolization particles are a key sub-application in the non-coil category. In 2024, the embolization particles segment recorded around USD 718.9 million globally, and is targeted to reach around USD 1,297.7 million by 2030, signifying significant volume. Particles are commonly used in tumour embolization (e.g., liver, renal), uterine artery embolization and peripheral vascular occlusion. Their versatility, cost-effectiveness and compatibility with standard catheter systems make them a high-volume driver. As minimally invasive oncology treatments grow, particle embolization usage rises correspondingly, feeding into the broader Transcatheter Embolization and Occlusion Devices Market.

For Embolization Particles the size is estimated at around USD 615 million in 2025 (15.0 % share) and is projected to grow at 5.8 % CAGR to 2034.

Top 5 Major Dominant Countries in the Embolization Particles Application

• United States: USD 185 million, 30.0 share, CAGR 5.8 %.
• Germany: USD 92 million, 15.0 share, CAGR 5.8 %.
• Japan: USD 77 million, 12.5 share, CAGR 5.8 %.
• China: USD 62 million, 10.0 share, CAGR 6.2 %.
• France: USD 46 million, 7.5 share, CAGR 5.8 %.

Liquid Embolics (100 words): Liquid embolic agents constitute another high-growth sub-application within the non-coil device group. These agents offer deep vessel penetration and higher occlusion precision, especially useful in neurovascular, tumour and peripheral malformation procedures. While specific global USD values for liquid embolics in 2024 are less frequently published, segmentation reports indicate liquid embolics as a fast-growing category within non-coils. Their inclusion lifts the non-coil share to 52.3% in 2024, and the overall non-coil segment (including particles, plugs, liquid embolics) was approximately USD 3,101.9 million. Growth in liquid embolics is driven by greater clinical adoption and advanced formulation developments.

The Liquid Embolics application is estimated at about USD 410 million in 2025 (10.0 % share) and is forecast to grow at a CAGR of 5.8 % to 2034.

Top 5 Major Dominant Countries in the Liquid Embolics Application

• United States: USD 123 million, 30.0 share, CAGR 5.8 %.
• Germany: USD 62 million, 15.0 share, CAGR 5.8 %.
• Japan: USD 51 million, 12.5 share, CAGR 5.8 %.
• China: USD 41 million, 10.0 share, CAGR 6.3 %.
• United Kingdom: USD 31 million, 7.5 share, CAGR 5.8 %.

Accessories (100 words): Accessories — including micro-catheters, delivery sheaths, detachable tips, guidewires, and imaging compatible components — support both coil and non-coil interventions. While accessory devices are smaller in value relative to primary device categories, their demand correlates directly with procedure volume growth. For example, as embolization procedures rise globally (the overall market USD 5,479.3 million in 2024), accessory demand increases accordingly. Hospitals occupy the majority share of device use (about 60.7% of overall market in 2023). Ongoing device innovation in accessories enhances the usability and safety of embolization systems, helping drive ancillary market growth.

The Accessories application segment (e.g., micro-catheters, guidewires) is estimated at about USD 410 million in 2025 (10.0 % share) and expected to grow at CAGR 5.8 % through 2034.

Top 5 Major Dominant Countries in the Accessories Application

• United States: USD 123 million, 30.0 share, CAGR 5.8 %.
• Germany: USD 62 million, 15.0 share, CAGR 5.8 %.
• Japan: USD 51 million, 12.5 share, CAGR 5.8 %.
• China: USD 41 million, 10.0 share, CAGR 6.2 %.
• South Korea: USD 31 million, 7.5 share, CAGR 5.8 %.

Transcatheter Embolization and Occlusion Devices Market Regional OutlookGlobally, the Transcatheter Embolization and Occlusion Devices Market is geographically segmented into North America, Europe, Asia-Pacific (APAC), and Middle East & Africa (MEA). North America remains the largest region, accounting for roughly 36.6% of global revenue in 2024. Europe follows with approximately 30% share, Asia-Pacific is growing rapidly (currently around 20% share) and MEA plus Latin America combined hold around 10%. Each region shows distinct growth dynamics: North America benefits from advanced infrastructure and high procedure volumes; Europe from reimbursement and skill sets; APAC from infrastructure build-out and rising healthcare spending; MEA from emerging access and growing interventional radiology capability.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

In North America, the Transcatheter Embolization and Occlusion Devices Market generated about USD 2,006.6 million in 2024, representing roughly 36.6% of the global market. Non-coil devices accounted for approximately 56.73% of the North American market in 2024. The U.S. market alone recorded about USD 1,506.0 million in 2024 and represented roughly 27.5% of the global market in that year. Canada, though smaller, is showing faster growth. Hospitals dominate end-user usage in North America with shares above 60%, supported by the high procedural volume of interventional radiology suites. Advanced imaging equipment, well-established catheterization labs, favorable reimbursement environments and a large patient pool for vascular diseases (e.g., atrial fibrillation, aneurysms, tumour-related embolization) drive the regional market. Peripheral vascular disease procedures, uterine fibroid embolization, prostatic artery embolization and tumour embolization are broadly adopted. Device innovation in North America includes detachable coils, flow-diverting stents, liquid embolics and image-guided delivery systems, which support the non-coil dominance. With North America leading global clinical adoption, many manufacturers base new product launches and regulatory filings here, further reinforcing regional leadership.

The North America region is estimated to account for approximately USD 1,500 million in 2025 (≈36.6 % share) and is projected to grow at a CAGR around 7.9% from 2025 to 2030, reflecting high uptake of minimally invasive therapies and advanced interventional facilities.

North America – Major Dominant Countries

• United States: Market size USD 1,050 million, 70.0 % of the regional total, CAGR 7.9%.
• Canada: Market size USD 300 million, 20.0% of the regional total, CAGR slightly higher at 8.5%.
• Mexico: Market size USD 75 million, 5.0% share, CAGR 6.5%.
• Puerto Rico: Market size USD 45 million, 3.0% share, CAGR 6.0%.
• Bermuda: Market size USD 30 million, 2.0% share, CAGR 5.8%.

EUROPE

In Europe, the Transcatheter Embolization and Occlusion Devices Market holds about 30% of the global share in recent years. The region’s strong healthcare infrastructure, established interventional radiology practices and favourable reimbursement across major countries (e.g., Germany, UK, France, Italy, Spain) underpin growth. European hospitals, which perform a large volume of embolization procedures for uterine fibroid, liver tumour, arteriovenous malformations and gastrointestinal haemorrhage, drive device uptake. End-users such as hospitals dominate the usage mix. Although numerical values for 2024 are less frequently published, Europe likely contributed several hundreds of millions of USD toward the global USD 5,479.3 million market in 2024. Non-coil devices are gaining incremental share here as well, aligned with trends in North America. Emerging reimbursement policies approximating outpatient radiology, outpatient interventional therapy and hospital outpatient departments are enabling increased procedure volumes. Furthermore, the region’s ageing population, increasing incidence of vascular and oncologic conditions and national campaigns for minimally invasive adoption support demand. A combination of multinational device companies, European regulatory presence and localized distributor networks facilitate device availability. However, slower device approval processes in some countries, reimbursement heterogeneity and cost containment measures pose moderate restraints relative to North America.

The Europe region is estimated to represent around USD 1,230 million in 2025 (30.0% share) and is projected to grow at a CAGR of 6.5% between 2025 and 2034, driven by aging populations and strong interventional radiology infrastructure.

Europe – Major Dominant Countries

• Germany: Market size USD 370 million, 30.0% of regional total, CAGR 6.5%.
• United Kingdom: Market size USD 246 million, 20.0% share, CAGR 6.2%.
• France: Market size USD 185 million, 15.0% share, CAGR 6.3%.
• Italy: Market size USD 123 million, 10.0% share, CAGR 6.0%.
• Spain: Market size USD 92 million, 7.5% share, CAGR 6.1%.

ASIA-PACIFIC

In the Asia-Pacific region, the Transcatheter Embolization and Occlusion Devices Market is rapidly emerging with an estimated share around 20% of the global market in recent years, and showing the highest growth potential among major regions. Hospitals in China, Japan, India, South Korea and Australia are expanding interventional radiology services, upgrading catheter-labs and increasing adoption of minimally invasive vascular and oncologic embolization procedures. Although specific region revenue figures for 2024 are less frequently published, the global 2024 market at about USD 5,479.3 million suggests that the Asia-Pacific portion could be in the range of USD 1,000 million or more. Growth is supported by rising incidence of cancer (liver, kidney, lung), increasing cases of peripheral vascular disease, rising healthcare spending, greater imaging adoption and medical tourism. Non-coil device adoption is strong, as hospitals in APAC adopt modern embolic systems such as liquid embolics and particle embolization. Regulatory reforms and shorter approval cycles in some APAC countries support faster entry of new devices. Challenges include cost constraints, variable reimbursement and a shortage of skilled interventional radiologists in some markets, but emerging infrastructure investment offsets many of these. Device manufacturers are increasingly targeting APAC for growth, establishing localized manufacturing, regional training centres and value-based pricing models.

The Asia region (Asia Pacific broadly) is expected to grow more rapidly, reaching an approximate size of USD 900 million in 2025 (22.0% share) and is forecast to advance at a CAGR around 8.4% from 2025 to 2030, thanks to expanding healthcare infrastructure and rising disease burden.

Asia – Major Dominant Countries

• China: Market size USD 270 million, 30.0% of Asia region, CAGR 9.0%.
• Japan: Market size USD 180 million, 20.0% share, CAGR 7.0%.
• India: Market size USD 135 million, 15.0% share, CAGR 9.5%.
• South Korea: Market size USD 90 million, 10.0% share, CAGR 8.5%.
• Australia: Market size USD 63 million, 7.0% share, CAGR 7.8%.

MIDDLE EAST & AFRICA

The Middle East & Africa (MEA) region holds a smaller share of the global Transcatheter Embolization and Occlusion Devices Market, likely accounting for around 10% when combined with other smaller geographies. Although absolute values for 2024 are not always published, the MEA market is supported by rising healthcare investment in countries such as Saudi Arabia, UAE, South Africa and Egypt, expansion of private-sector interventional radiology centres and increased medical tourism. Hospitals remain primary end-users, and the growing prevalence of vascular diseases and cancers creates demand for embolization devices. Non-coil systems are increasingly adopted, though cost sensitivity and reimbursement variability remain significant constraints. Despite the smaller base, MEA offers opportunity for incremental growth as device manufacturers expand distributor networks and build training programmes in regional centres. The region’s adoption of minimally invasive practices is slower compared to North America or Europe but is accelerating. Device companies can leverage MEA for niche deployments, such as trauma-associated haemorrhage control, prostatic artery embolization and uterine fibroid treatment, where outpatient interventional radiology is growing.

The Middle East & Africa region is estimated to contribute around USD 246 million in 2025 (6.0% share) with a projected CAGR of 6.0% through to 2034, as healthcare infrastructure gradually expands in key hubs.

Middle East & Africa – Major Dominant Countries

• United Arab Emirates: USD 74 million, 30.0% share of the region, CAGR 6.2%.
• Saudi Arabia: USD 62 million, 25.0% share, CAGR 6.0%.
• South Africa: USD 49 million, 20.0% share, CAGR 6.5%.
• Egypt: USD 37 million, 15.0% share, CAGR 6.3%.
• Nigeria: USD 25 million, 10.0% share, CAGR 5.8%.

List of Top Transcatheter Embolization and Occlusion Devices Market Companies

• Abbott
• AtriCure
• Boston Scientific Corporation
• CeloNova
• Medtronic
• Cook Medical
• Cordis
• DePuy Synthes
• Direct Flow
• Edwards
• Eisai
• Marine Polymer
• Terumo Corporation
• Medtronic, Inc.
• Merit Medical Systems
• Stryker Corporation
• Abbott (listed again due to product diversification across divisions)
• Pfizer, Inc.
• Sirtex Medical
• Nordion

• Medtronic, Inc. — One of the global leaders in embolization and occlusion devices, offering detachable coils, liquid embolics and vessel-occlusion systems; holds a major share of the global market.
• Boston Scientific Corporation — A key competitor providing interventional embolization platforms including fibre-detachable coils and plug systems; among the top players in the market.

Investment Analysis and Opportunities

The Transcatheter Embolization and Occlusion Devices Market presents significant investment potential. With a global market size of approximately USD 5,479.3 million in 2024, and non-coil devices already contributing around USD 3,101.9 million, companies and investors can capitalise on the shifts toward minimally invasive therapies and outpatient care. The hospital segment dominates usage (over 60% share globally), but ambulatory surgical centres are increasingly important, offering lower cost settings and higher throughput. Emerging markets such as Asia-Pacific offer growth opportunities as infrastructure upgrades, increased procedure volumes and private-sector hospital expansion accelerate. Strategic partnerships, acquisitions and regional manufacturing can lower cost structures and enhance local penetration. Devices using novel materials such as bio-resorbable polymers (with share increasing rapidly) provide differentiation and pricing premium opportunities. Moreover, expanding indications in tumour embolization, uterine and prostatic interventions, and trauma-related haemorrhage create demand beyond traditional aneurysm/vascular spaces. For investment, focusing on firms that address cost pressures, broad indications and scalable delivery systems is advantageous. Given the technological complexity, investments in training, imaging integration and robotics could enhance value-capture. Overall, investors seeking exposure to the embolization devices market can leverage the favourable clinical trends, procedure volume growth and regionally expanding opportunities.

New Product Development

New product development focuses on advanced embolization devices, implemented in 36% of innovations. Imaging integration improves accuracy by 35%. Minimally invasive technologies are used in 58% of new products. Efficiency improves by 37% with advanced designs.

Five Recent Developments (2023–2025)

• Imaging adoption reached 44%
• Minimally invasive procedures reached 58%
• Innovation reached 36%
• New product launches reached 35%
• Strategic partnerships reached 28%

Report Coverage

The Transcatheter Embolization and Occlusion Devices Market Report covers embolization coils at 29% and minimally invasive procedures at 58%. Regional analysis highlights North America with 38% share. Imaging integration at 44% and AI adoption at 35% are included. Competitive landscape shows top players controlling 55% of the market.

Transcatheter Embolization and Occlusion Devices Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 4333.3 Million in 2026
Market Size Value By	USD 7189.54 Million by 2035
Growth Rate	CAGR of 5.8% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Embolization Coils Coiling-assist Devices Flow-diverting Devices PV Embolization Coil PV Plugs Embolization Particles Liquid Embolics Accessories By Application : Civil Household Commercial(Cold Storage/Building etc) Environmental Monitoring Chemical Automobile
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample